Novakand Pharma AB (publ) (LARK) — Working Capital to Net Assets Ratio
Novakand Pharma AB (publ) (LARK) has a Working Capital to Net Assets ratio of 9.8% as of December 2025. Working capital of Skr5.42 Million (current assets of Skr6.66 Million minus current liabilities of Skr1.24 Million) is measured against net assets of Skr55.49 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See LARK financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Novakand Pharma AB (publ) Working Capital to Net Assets (2012–2025)
This chart shows how Novakand Pharma AB (publ)'s Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 9.8%, reflecting working capital of Skr5.42 Million against net assets of Skr55.49 Million SEK. See LARK cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Novakand Pharma AB (publ) (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Novakand Pharma AB (publ) from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see LARK market cap overview.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 9.8% | Skr5.42 Million | Skr55.49 Million | Skr6.66 Million | Skr1.24 Million | ▼ -89.2 pp |
| 2024 | 98.9% | Skr70.82 Million | Skr71.58 Million | Skr75.12 Million | Skr4.30 Million | ▲ +13.9 pp |
| 2023 | 85.1% | Skr99.08 Million | Skr116.46 Million | Skr103.24 Million | Skr4.16 Million | ▼ -2.4 pp |
| 2022 | 87.5% | Skr133.12 Million | Skr152.12 Million | Skr139.22 Million | Skr6.10 Million | ▲ +1.2 pp |
| 2021 | 86.4% | Skr136.68 Million | Skr158.28 Million | Skr144.62 Million | Skr7.94 Million | ▲ +20.0 pp |
| 2020 | 66.3% | Skr47.39 Million | Skr71.43 Million | Skr55.37 Million | Skr7.98 Million | ▲ +89.1 pp |
| 2019 | -22.8% | Skr-4.63 Million | Skr20.30 Million | Skr18.88 Million | Skr23.51 Million | ▼ -114.7 pp |
| 2018 | 91.9% | Skr18.80 Million | Skr20.46 Million | Skr33.46 Million | Skr14.66 Million | ▲ +10.7 pp |
| 2017 | 81.2% | Skr5.29 Million | Skr6.51 Million | Skr6.92 Million | Skr1.63 Million | ▲ +11.2 pp |
| 2016 | 70.0% | Skr2.86 Million | Skr4.08 Million | Skr3.67 Million | Skr809.66K | ▼ -18.0 pp |
| 2015 | 88.0% | Skr9.04 Million | Skr10.27 Million | Skr9.73 Million | Skr691.73K | ▲ +3.0 pp |
| 2014 | 85.0% | Skr4.82 Million | Skr5.67 Million | Skr5.40 Million | Skr582.04K | ▲ +88.9 pp |
| 2013 | -3.8% | Skr-23.01K | Skr598.60K | Skr17.97K | Skr40.98K | ▲ +90.2 pp |
| 2012 | -94.0% | Skr-280.30K | Skr298.09K | Skr16.28K | Skr296.58K | — |